Company news
Invion Ltd. (ASX:IVX) news
Every Invion Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Appendix 4C and Quarterly Activities Report - June 2026
July 30, 2026
Photosoft Platform Expands to Eye Diseases Via Partnership
May 18, 2026
Appendix 4C and Quarterly Activities Report - March 2026
April 30, 2026
Skin Cancer Trial Moves to BCC With More Encouraging Signals
April 21, 2026
Appendix 4D and Half Year Financial Report
February 26, 2026
Appendix 4C and Quarterly Activities Report - December 2025
January 30, 2026
Major Shareholders Lead Invion $1.3M Capital Raise
January 30, 2026
Trading Halt
January 28, 2026
Pause in Trading
January 28, 2026
Hanlim & Korean Government Fund Pathway to Clinical Trial
December 22, 2025
Invion Secures Expanded Photosoft Global Exclusive License
December 2, 2025
Appendix 4C and Quarterly Activities Report - September 2025
October 30, 2025
Funded Collaboration Agreement with Protect Animal Health
October 20, 2025
Repayment of Lind Facility with Successful Capital Raise
October 9, 2025
Response to ASX Aware Letter
August 27, 2025
Appendix 4E and Annual Report
August 27, 2025
Response to ASX Price Query
August 20, 2025
Orphan Drug Designation Granted by U.S. FDA For Anal Cancer
August 20, 2025
Appendix 4C and Quarterly Activities Report - June 2025
July 31, 2025
Security Class Reinstatement to Quotation
July 17, 2025
Security Class Suspension from Quotation
July 10, 2025
Underwritten Loyalty Option Entitlement Offer Prospectus
June 23, 2025
EQR Progresses Regional Tungsten Hub Strategy
June 13, 2025
Loyalty Option Entitlement Offer
June 13, 2025
Encouraging SRC Findings on Ph I/II Skin Cancer Trial
May 28, 2025
Dosing of 1st Six Patients in Phase I/II Skin Cancer Trial
May 1, 2025
Appendix 4C and Quarterly Activities Report - March 2025
April 30, 2025
Share Purchase Agreement Termination and Tranche Repayment
March 4, 2025
Completion Of Placement to Accelerate Clinical Programs
March 4, 2025
Oesophageal Cancer Collaboration and Funding Agreement
February 25, 2025
Activities Report and Appendix 4C
January 30, 2025
Invion Doses First Patient in Phase I/II Skin Cancer Trial
December 2, 2024
Consolidation/Split - IVX
October 14, 2024
Ph 2 Prostate Cancer Results Strong Safety and 40% Response
September 17, 2024
Invion secures funding through an institutional placement
June 27, 2024
Agreement with Major South Korean Pharma Group Hanlim
May 7, 2024
INV043 With ICI Therapy Achieved 80% Tumour Control For ASCC
March 4, 2024
Agreement with Dr.inB to develop Photosoft treatment for HPV
February 22, 2024
AGM Presentation
November 28, 2023
Major Milestone towards Clinical Trials
November 21, 2023
Investor Presentation
October 23, 2023
Photosoft Territory Expanded to South Korea for Cancer
September 24, 2023
Appendix 4E and Preliminary Financial Report
August 30, 2023
Expansion of Territory Rights to USA, Canada and Hong Kong
February 7, 2023
INV043 Effective Against Anal Cancer SCC In Vitro
September 14, 2022
Response to ASX Aware Query
September 13, 2022
Photosoft Shows Activity Against Zika Virus
September 7, 2022
Invion : Activities Report and Appendix 4C
July 20, 2022
INV043 SIGNIFICANTLY IMPROVED CHECKPOINT INHIBITOR THERAPY
May 29, 2022
Supplementary Prospectus
November 25, 2021